Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 300-307

  Papakostas, George I ^a   Charles, Dana ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Depression; Dose; Efficacy; SSRI; Tolerability

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGITATION; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FLUOXETINE; FLUVOXAMINE; HUMANS; PAROXETINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 77950833522     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970701432528     Document Type: Article

References (32)

1. Amin M, Lehmann H, Mirmiran J. 1989. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 25:164-167.
2. Bech P, Tanghoj P, Andersen HF, et al. 2002. Citalopram doseresponse revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berlin) 163:20-25.
3. Bech P, Tanghoj P, Cialdella P, et al. 2004. Escitalopram doseresponse revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 7:283-290.
4. Bech P, Andersen HF, Wade A. 2006. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 39:128-134.
5. Burke WJ, Gergel I, Bose A. 2002. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
6. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
7. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. 1989. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 25:71-79.
8. Dunlop SR, Dornseif BE, Wernicke JF, et al. 1990. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 26:173-180.
9. Fabre LF, Putman HP. 1987. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 48:406-408.
10. Fabre LF, Abuzzahab FS, Amin M, et al. 1995. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38:592-602.
11. Feighner JP, Ø K, Multicenter. 1999. Placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 60:824-830.
12. Fieve RR, Goodnick PJ, Peselow ED, Barouche F, Schlegel A. 1986a. Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry 47:560-562.
13. Fieve RR, Goodnick PJ, Peselow E, Schlegel A. 1986b. Fluoxetine response: endpoint vs pattern analysis. Int Clin Psychopharmacol 1:320-323.
14. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17:1-12.
16. Laird NM, Mosteller F. 1990. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 6:5-30.
17. Montgomery SA, Asberg A. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382- 389.
18. Montgomery SA, Rasmussen JG, Lyby K, et al. 1992. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 6(Suppl 5):65-70.
19. Mosteller F, Colditz GA. 1996. Understanding research synthesis (meta-analysis). Annu Rev Public Health 17:1-23.
20. Nemeroff CB, Entsuah R, Willard LB, et al. 2003. Comprehensive pooled analysis of remission data: venlafaxine vs SSRIs (compare). American Psychiatric Association Annual Meeting.
21. Papakostas GI, Fava M. 2005. Monoamine-based pharmacotherapy. In: Licinio J, editor. Biology of depression: From novel insights to therapeutic strategies. 1st ed. Weinheim: Wiley-VCH Verlag. pp 87-140.
22. Papakostas GI, Fava M. 2006a. Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Neuropsychopharmacology 31(Suppl 1):s158.
23. Papakostas GI, Schwartz TL. 2006b. Pharmacotherapeutic strategies to enhance tolerability and adherence in MDD. In: Petersen TJ, Schwartz TL, editors. Depression: Treatment strategies and management Vol. 1. New York: Taylor & Francis. pp 201-215.
24. Papakostas GI, Petersen T, Denninger JW, et al. 2004. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 24:507-511.
25. Paykel ES, Ramana R, Cooper Z, et al. 1995. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
26. Petersen T, Dording C, Neault NB, et al. 2002. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 26:177-187.
27. Petersen T, Papakostas GI, Posternak MA, et al. 2005. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 25:336-341.
28. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. 1990. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 51:8-11.
29. Trivedi MH, Pigotti TA, Perera P, et al. 2004. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 65:1356-1364.
30. Walczak DD, Apter JT, Halikas JA, et al. 1996. The oral doseeffect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 8:139-151.
31. Wernicke JF, Dunlop SR, Dornseif BE, et al. 1987. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 23:164-168.
32. Wernicke JF, Dunlop SR, Dornseif BE, et al. 1988. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24:183-188.